Table 2.

IRs and HRs with 95% CIs of different types of second primary solid tumors and hematological malignancies other than NHL and MDS/AML, comparing lymphoma patients diagnosed 1993-2014, with follow-up through 2017, to matched population comparators in Sweden

Events, nMedian time to event years (IQR)Rate (per 1000 person-years)HR (95% CI)*P
Solid tumors 
Lip, oral cavity, pharynx, upper respiratory system 
 Comparator 560 5.8 (2.8-7) 0.4 (0.4-0.4) 1.0 (ref) <.001 
 Case 117 4.3 (2.7-8.4) 0.6 (0.5-0.8) 1.8 (1.5-2.2) 
Gastrointestinal tract 
 Comparator 5182 5.7 (2.6-10.0) 3.5 (3.4-3.6) 1.0 (ref) <.001 
 Case 742 4.6 (2.1-8.5) 4.0 (3.7-4.3) 1.27 (1.2-1.4) 
Lower respiratory system 
 Comparator 1926 5.6 (2.6-9.8) 1.3 (1.2-1.4) 1.0 (ref) <.001 
 Case 331 5.2 (2.5-9.9) 1.8 (1.6-2.0) 1.5 (1.3-1.6) 
Thymus, bone cartilage and soft tissue sarcoma 
 Comparator 215 4.5 (2.3-9.6) 0.1 (0.1-0.2) 1.0 (ref) <.001 
 Case 43 5.2 (2.6-9.3) 0.2 (0.2-0.3) 1.7 (1.2-2.4) 
Melanoma 
 Comparator 1136 6.2 (2.9-11.1) 0.8 (0.7-0.8) 1.0 (ref) <.001 
 Case 224 4.8 (2.2-8.7) 1.2 (1.1-1.4) 1.7 (1.5-2.0) 
Nonmelanoma skin cancer 
 Comparator 2691 6.1 (2.8-10.9) 1.8 (1.8-1.9) 1.0 (ref) <.001 
 Case 952 4.3 (2.0-8.2) 5.2 (4.8-5.5) 3.6 (3.3-3.8) 
Breast 
 Comparator 2265 5.6 (2.6-9.8) 1.5 (1.5-1.6) 1.00 (ref) .252 
 Case 258 5.9 (2.8-10.7) 1.4 (1.2-1.6) 0.9 (0.8-1.1) 
Female genital organs 
 Comparator 1041 5.2 (2.5-9.6) 1.5 (1.4-1.6) 1.00 (ref) .047 
 Case 103 5.1 (1.5-8.5) 1.2 (1.0-1.5) 0.8 (0.7-1.0) 
Male genital organs 
 Comparator 5574 5.6 (2.5-9.8) 7.2 (7.0-7.4) 1.00 (ref) .578 
 Case 631 5.2 (2.3-9.3) 6.4 (5.9-6.9) 1.0 (0.9-1.1) 
Urinary tract 
 Comparator 2156 5.5 (2.7-10.0) 1.5 (1.4-1.5) 1.0 (ref) <.001 
 Case 328 4.0 (1.2-8.4) 1.8 (1.6-2.0) 1.3 (1.2-1.5) 
Central nervous system 
 Comparator 435 5.5 (2.5-9.1) 0.3 (0.3-0.3) 1.0 (ref) .087 
 Case 69 4.4 (1.5-8.9) 0.4 (0.3-0.5) 1.3 (1.0-1.6) 
Endocrine system 
 Comparator 337 4.8 (2.3-8.5) 0.2 (0.2-0.3) 1.0 (ref) <.001 
 Case 73 2.3 (1.3-6.4) 0.4 (0.3-0.5) 1.7 (1.3-2.1) 
Ill-defined/unknown primary site 
 Comparator 796 5.0 (2.3-9.1) 0.5 (0.5-0.6) 1.0 (ref) <.001 
 Case 145 4.2 (1.5-7.0) 0.8 (0.7-0.9) 1.6 (1.3-1.9) 
Hematological malignancies other than NHL and MDS/AML 
CML/MPN 
 Comparator 226 5.9 (3.0-11.7) 0.2 (0.1-0.2) 1.0 (ref) .036 
 Case 39 3.5 (2.1-5.4) 0.2 (0.2-0.3) 1.4 (1.0-2.0) 
Hodgkin lymphoma 
 Comparator 33 6.0 (2.6-9.2) 0.02 (0.02-0.03) 1.0 (ref) <.001 
 Case 37 6.0 (3.3-7.7) 0.2 (0.1-0.3) 8.7 (5.4-13.4) 
Multiple myeloma 
 Comparator 327 5.7 (2.6-9.4) 0.2 (0.2-0.2) 1.0 (ref) .854 
 Case 37 4.9 (2.6-8.6) 0.2 (0.1-0.3) 1.0 (0.7-1.4) 
Lymphatic leukemia† 
 Comparator 37 5.4 (2.9-8.6) 0.02 (0.02-0.03) 1.0 (ref) <.001 
 Case 17 3.4 (1.2-5.9) 0.1 (0.1-0.1) 3.7 (2.1-6.6) 
Events, nMedian time to event years (IQR)Rate (per 1000 person-years)HR (95% CI)*P
Solid tumors 
Lip, oral cavity, pharynx, upper respiratory system 
 Comparator 560 5.8 (2.8-7) 0.4 (0.4-0.4) 1.0 (ref) <.001 
 Case 117 4.3 (2.7-8.4) 0.6 (0.5-0.8) 1.8 (1.5-2.2) 
Gastrointestinal tract 
 Comparator 5182 5.7 (2.6-10.0) 3.5 (3.4-3.6) 1.0 (ref) <.001 
 Case 742 4.6 (2.1-8.5) 4.0 (3.7-4.3) 1.27 (1.2-1.4) 
Lower respiratory system 
 Comparator 1926 5.6 (2.6-9.8) 1.3 (1.2-1.4) 1.0 (ref) <.001 
 Case 331 5.2 (2.5-9.9) 1.8 (1.6-2.0) 1.5 (1.3-1.6) 
Thymus, bone cartilage and soft tissue sarcoma 
 Comparator 215 4.5 (2.3-9.6) 0.1 (0.1-0.2) 1.0 (ref) <.001 
 Case 43 5.2 (2.6-9.3) 0.2 (0.2-0.3) 1.7 (1.2-2.4) 
Melanoma 
 Comparator 1136 6.2 (2.9-11.1) 0.8 (0.7-0.8) 1.0 (ref) <.001 
 Case 224 4.8 (2.2-8.7) 1.2 (1.1-1.4) 1.7 (1.5-2.0) 
Nonmelanoma skin cancer 
 Comparator 2691 6.1 (2.8-10.9) 1.8 (1.8-1.9) 1.0 (ref) <.001 
 Case 952 4.3 (2.0-8.2) 5.2 (4.8-5.5) 3.6 (3.3-3.8) 
Breast 
 Comparator 2265 5.6 (2.6-9.8) 1.5 (1.5-1.6) 1.00 (ref) .252 
 Case 258 5.9 (2.8-10.7) 1.4 (1.2-1.6) 0.9 (0.8-1.1) 
Female genital organs 
 Comparator 1041 5.2 (2.5-9.6) 1.5 (1.4-1.6) 1.00 (ref) .047 
 Case 103 5.1 (1.5-8.5) 1.2 (1.0-1.5) 0.8 (0.7-1.0) 
Male genital organs 
 Comparator 5574 5.6 (2.5-9.8) 7.2 (7.0-7.4) 1.00 (ref) .578 
 Case 631 5.2 (2.3-9.3) 6.4 (5.9-6.9) 1.0 (0.9-1.1) 
Urinary tract 
 Comparator 2156 5.5 (2.7-10.0) 1.5 (1.4-1.5) 1.0 (ref) <.001 
 Case 328 4.0 (1.2-8.4) 1.8 (1.6-2.0) 1.3 (1.2-1.5) 
Central nervous system 
 Comparator 435 5.5 (2.5-9.1) 0.3 (0.3-0.3) 1.0 (ref) .087 
 Case 69 4.4 (1.5-8.9) 0.4 (0.3-0.5) 1.3 (1.0-1.6) 
Endocrine system 
 Comparator 337 4.8 (2.3-8.5) 0.2 (0.2-0.3) 1.0 (ref) <.001 
 Case 73 2.3 (1.3-6.4) 0.4 (0.3-0.5) 1.7 (1.3-2.1) 
Ill-defined/unknown primary site 
 Comparator 796 5.0 (2.3-9.1) 0.5 (0.5-0.6) 1.0 (ref) <.001 
 Case 145 4.2 (1.5-7.0) 0.8 (0.7-0.9) 1.6 (1.3-1.9) 
Hematological malignancies other than NHL and MDS/AML 
CML/MPN 
 Comparator 226 5.9 (3.0-11.7) 0.2 (0.1-0.2) 1.0 (ref) .036 
 Case 39 3.5 (2.1-5.4) 0.2 (0.2-0.3) 1.4 (1.0-2.0) 
Hodgkin lymphoma 
 Comparator 33 6.0 (2.6-9.2) 0.02 (0.02-0.03) 1.0 (ref) <.001 
 Case 37 6.0 (3.3-7.7) 0.2 (0.1-0.3) 8.7 (5.4-13.4) 
Multiple myeloma 
 Comparator 327 5.7 (2.6-9.4) 0.2 (0.2-0.2) 1.0 (ref) .854 
 Case 37 4.9 (2.6-8.6) 0.2 (0.1-0.3) 1.0 (0.7-1.4) 
Lymphatic leukemia† 
 Comparator 37 5.4 (2.9-8.6) 0.02 (0.02-0.03) 1.0 (ref) <.001 
 Case 17 3.4 (1.2-5.9) 0.1 (0.1-0.1) 3.7 (2.1-6.6) 
*

Mutually adjusted for sex, age at diagnosis, and calendar year of diagnosis.

†

ALL and lymphoblastic/lymphocytic leukemia unspecified.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal